Abstract
A single oral dose of sotalol (160 mg) was administered to control subjects with normal renal function and patients with chronic renal failure in the interdialysis period to estimate the elimination kinetics of the drug. Sotalol concentrations in body fluids were measured fluorimetrically using a modified Garrett and Schnelle (1971) method. Mean plasma half-life (T 1/2) was approximately 5 h in normals, 42 h in patients off-dialysis. During haemodialysis the mean plasma half-time was on the average 7 hours. Comulative urinary excretion of the drug was considerably lower in the patient group: 9% of the dose in 48 h as opposed to 61% in normals. Comparison of sotalol concentrations in plasma versus ultrafiltrate from the coil kidney indicates that the drug in vivo is negligible bound to plasma proteins in remal patients. The net-lowering effect of a 6 to 7 h haemodialysis on the plasma concentration decay line was by 20%. Post-dialysis plasma concentration data suggest that the rate at which sotalol returns to plasma from body tissues appears to be the rate-controlling factor in the elimination of sotalol by haemodialysis.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bodem G., Chidsey C. A. Pharmacokinetic studies of practolol, a beta adrenergic antagonist, in man. Clin Pharmacol Ther. 1973 Jan-Feb;14(1):26–29. doi: 10.1002/cpt197314126. [DOI] [PubMed] [Google Scholar]
- Dunlop D., Shanks R. G. Selective blockade of adrenoceptive beta receptors in the heart. Br J Pharmacol Chemother. 1968 Jan;32(1):201–218. doi: 10.1111/j.1476-5381.1968.tb00444.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Garrett E. R., Schnelle K. Separation and spectrofluorometric assay of the -adrenergic blocker sotalol from blood and urine. J Pharm Sci. 1971 Jun;60(6):833–839. doi: 10.1002/jps.2600600607. [DOI] [PubMed] [Google Scholar]
- Harvengt C., Desager J. P., Muschart J. M., Tjandramaga Y. B., Verbeeck R., Verberckmoes R. Influence of the hemodialysis on the half-life of practolol in patients with severe renal failure. J Clin Pharmacol. 1975 Aug-Sep;15(8-9):605–610. doi: 10.1002/j.1552-4604.1975.tb02379.x. [DOI] [PubMed] [Google Scholar]
- Iisalo E., Forsström J. Elimination of digoxin during maintenance haemodialysis. Ann Clin Res. 1974 Aug;6(4):203–206. [PubMed] [Google Scholar]
- Lish P. M., Shelanski M. V., LaBudde J. A., Williams W. R. Inhibition of cardiac chronotropic action of isoproterenol by Sotalol (MJ 1999) in rat, dog and man. Curr Ther Res Clin Exp. 1967 Jun;9(6):311–324. [PubMed] [Google Scholar]
- Lish P. M., Weikel J. H., Dungan K. W. Pharmacological and toxicological properties of two new beta-adrenergic receptor antagonists. J Pharmacol Exp Ther. 1965 Aug;149(2):161–173. [PubMed] [Google Scholar]
- Raper C., Wale J. Propranolol, MJ 1999 and Ciba 39089 Ba in ouabain and adrenaline induced cardiac arrhythmias. Eur J Pharmacol. 1968 Aug;4(1):1–12. doi: 10.1016/0014-2999(68)90002-2. [DOI] [PubMed] [Google Scholar]
- Schneck D. W., Aoki V. S., Kroetz F. W., Wilson W. R. Correlation of beta blockade with serum practolol levels after oral administration. Clin Pharmacol Ther. 1972 Sep-Oct;13(5):685–693. doi: 10.1002/cpt1972135part1685. [DOI] [PubMed] [Google Scholar]
- Sundquist H., Anttila M., Arstila M. Antihypertensive effects of practolol and sotalol. Clin Pharmacol Ther. 1974 Sep;16(3):465–472. doi: 10.1002/cpt1974163part1465. [DOI] [PubMed] [Google Scholar]